Eurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19
Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19.
Eurocine Vaccines has signed an evaluation agreement, a Material Transfer Agreement, with an innovative, North American, small public company, regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19. Studies in one or two animal species will be conducted to study both potency and safety.
Endocine™ is Eurocine Vaccines' proprietary adjuvant platform based on natural lipid compounds and formulated as a liposomal dispersion. The manufacture of bulk adjuvant has been established in pilot-scale at GMP conditions and shown excellent safety and tolerability in more than 400 human subjects after nasal administration in five clinical trials.
The platform Endocine™ has been evaluated with several different vaccine antigens, both viral and bacterial, and found compatible with peptides, proteins, polysaccharides, VLPs, as well as split and whole pathogens.
More about Endocine™ can be found at:
https://www.eurocine-vaccines.com/the-portfolio/
If positive data are obtained using Endocine™, the technology may be applied using other vaccine candidates in the collaboration.
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market. The company operates in the heart of the bio-scientific cluster at Karolinska Institutet.
The main focus is on developing a broad vaccine portfolio. Through this portfolio strategy, more innovations are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. The vaccines are later licensed to partners for further development and commercialization.
The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.
Many internationally merited vaccine specialists have been attracted to the board of Eurocine Vaccines.
The head office is located in Solna, Sweden.
Eurocine Vaccines, EUCI, is listed on Spotlight Stock Market, XSAT.
